Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Go back to Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides| TOOTSIE ROLL INDUSTRIES, Inc. (NYSE: TR) | Delayed: 38.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.27 | 52 Week High | $39.62 | |||
| Open | $38.27 | 52 Week Low | $29.91 | |||
| Day High | $38.27 | P/E | 40.71 | |||
| Day Low | $38.27 | EPS | $0.94 | |||
| Volume | 36 | |||||
| (NASDAQ: TRIL) | Delayed: 19.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.86 | 52 Week High | $17.70 | |||
| Open | $19.86 | 52 Week Low | $6.62 | |||
| Day High | $19.86 | P/E | N/A | |||
| Day Low | $19.86 | EPS | $0.00 | |||
| Volume | 13,227 | |||||
